A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 in Subjects With Relapsed or Refractory Haematologic Malignancies
Phase of Trial: Phase I
Latest Information Update: 15 Oct 2018
At a glance
- Drugs AZD 5991 (Primary)
- Indications Chronic lymphocytic leukaemia; Multiple myeloma; Non-Hodgkin's lymphoma; T cell lymphoma
- Focus Adverse reactions
- Sponsors AstraZeneca
- 08 Oct 2018 Planned number of patients changed from 30 to 48.
- 26 Jun 2018 Planned End Date changed from 12 Aug 2019 to 23 Oct 2019.
- 26 Jun 2018 Planned primary completion date changed from 12 Aug 2019 to 23 Oct 2019.